Alterity Therapeutics confirmed FDA agreement on the Phase 3 trial design for ATH434 targeting Multiple System Atrophy (MSA) and secured a new U.S. patent extending protection to 2045. The company has begun operational activities for the trial, which will enroll about 200 patients. Financially, Alterity holds A$41.3 million in cash, supported by recent option exercises and an R&D tax refund. These developments strengthen its position as it advances ATH434's clinical development and explores strategic partnerships to maximize shareholder value.
Alterity Therapeutics' recent corporate update and Q1 FY27 cash flow report provide context for readers following healthcare developments. For readers following the health sector, here is Pluang's market snapshot as of Oct 30, 2026 18:11 WIB: Among 150 priced US health stocks, 75 rose and 70 fell. Notable movers include BTSG at USD 64.15 with a 6.53% increase and Pluang order activity of 10% Sell / 90% Buy and a typical hold time of 10 days; TWST at USD 162.37 down 6.39% with 36% Sell / 64% Buy and a 27-day hold; and CTXR at USD 0.60 up 6.32% with 100% Sell / 0% Buy and an 18-day hold time.
As Halloween approaches, MADD Canada warns against impaired driving caused by alcohol, cannabis, or drugs, which leads to hundreds of deaths and thousands of injuries annually in Canada. The organization urges people to plan safe transportation if co...
MADD Canada warns Canadians to avoid impaired driving during Halloween, emphasizing the risks of alcohol, cannabis, and drug-related crashes that cause deaths and injuries annually. The organization urges people to plan safe rides, watch for children...
Investec Bank Plc, acting as joint broker for SThree Plc, disclosed share transactions on October 29, 2026. The bank purchased and sold 49,799 ordinary shares of SThree Plc at prices ranging between 297.5 and 306.5 per share. No derivative or option ...
Investec Bank plc, acting as joint broker for Gamma Communications Plc, disclosed its share dealings on October 29, 2026. The bank purchased 218,193 ordinary shares at prices between 1091 and 1094 pence per share and sold 160,410 shares at prices bet...
Investec Bank Plc, acting as advisor and joint broker to Advanced Medical Solutions Group Plc, disclosed its share dealings on October 29, 2026. The bank purchased 10,640 ordinary shares at a price of 282.75 per share and sold 98 shares at 283 each. ...
